Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK
Open Access
- 6 February 2021
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-12
Abstract
Background: The PI 3-kinase (PI3K) pathway has been implicated as a target for melanoma therapy. Methods: Given the high degree of genetic heterogeneity in melanoma, we sought to understand the breadth of variation in PI3K signalling in the large NZM panel of early passage cell lines developed from metastatic melanomas. Results: We find the vast majority of lines show upregulation of this pathway, and this upregulation is achieved by a wide range of mechanisms. Expression of all class-IA PI3K isoforms was readily detected in these cell lines. A range of genetic changes in different components of the PI3K pathway was seen in different lines. Coding variants or amplification were identified in the PIK3CA gene, and amplification of the PK3CG gene was common. Deletions in the PIK3R1 and PIK3R2 regulatory subunits were also relatively common. Notably, no genetic variants were seen in the PIK3CD gene despite p110δ being expressed in many of the lines. Genetic variants were detected in a number of genes that encode phosphatases regulating the PI3K signalling, with reductions in copy number common in PTEN, INPP4B, INPP5J, PHLLP1 and PHLLP2 genes. While the pan-PI3K inhibitor ZSTK474 attenuated cell growth in all the lines tested, isoform-selective inhibition of p110α and p110δ inhibited cell growth in only a subset of the lines and the inhibition was only partial. This suggests that functional redundancy exists between PI3K isoforms. Furthermore, while ZSTK474 was initially effective in melanoma cells with induced resistance to vemurafenib, a subset of these cell lines concurrently developed partial resistance to PI3K inhibition. Importantly, mTOR-selective or mTOR/PI3K dual inhibitors effectively inhibited cell growth in all the lines, including those already resistant to BRAF inhibitors and ZSTK474. Conclusions: Overall, this indicates a high degree of diversity in the way the PI3K pathway is activated in different melanoma cell lines and that mTOR is the most effective point for targeting the growth via the PI3K pathway across all of these cell lines.Keywords
Funding Information
- Cancer Society of New Zealand
- Health Research Council of New Zealand
- Maurice Wilkins Centre for Molecular Biodiscovery
This publication has 59 references indexed in Scilit:
- Signatures of mutational processes in human cancerNature, 2013
- Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivoBiochemical Journal, 2012
- A drug targeting only p110α can block phosphoinositide 3-kinase signalling and tumour growth in certain cell typesBiochemical Journal, 2011
- Inositol polyphosphate 4-phosphatase II regulates PI3K/Akt signaling and is lost in human basal-like breast cancersProceedings of the National Academy of Sciences, 2010
- Cancer-derived mutations in the regulatory subunit p85α of phosphoinositide 3-kinase function through the catalytic subunit p110αProceedings of the National Academy of Sciences, 2010
- Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)Biochemical Journal, 2009
- PTEN-deficient cancers depend on PIK3CBProceedings of the National Academy of Sciences, 2008
- Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityProceedings of the National Academy of Sciences, 2008
- Evidence for functional redundancy of class IA PI3K isoforms in insulin signallingBiochemical Journal, 2007
- Mutations of the BRAF gene in human cancerNature, 2002